Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.72
-0.0100-0.58%
Post-market: 1.70-0.0200-1.16%19:58 EDT
Volume:563.44K
Turnover:977.33K
Market Cap:91.96M
PE:-2.58
High:1.79
Open:1.72
Low:1.67
Close:1.73
Loading ...

Milestone Pharmaceuticals FY 2024 GAAP EPS $(0.67) Misses $(0.62) Estimate, Cash Balance Of $69.7M

Benzinga
·
13 Mar

Milestone Pharmaceuticals Inc: Q4 Shr Loss $-0.19

THOMSON REUTERS
·
13 Mar

Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Dow Jones
·
13 Mar

Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule

TIPRANKS
·
04 Mar

TD Cowen Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)

TIPRANKS
·
02 Mar

Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Milestone Pharmaceuticals (MIST) and Personalis (PSNL)

TIPRANKS
·
28 Feb

Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

DONNA KARAN CASHMERE MIST INTRODUCES A NEW CHAPTER FOR SPRING 2025, FEATURING IMAAN HAMMAM IN A CAPTIVATING CAMPAIGN

PR Newswire
·
28 Feb

Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray

MT Newswires Live
·
19 Feb

BRIEF-Milestone Pharmaceuticals Inc Receives Notice Of Allowance On New U.S. Patent For Etripamil

Reuters
·
19 Feb

Milestone receives notice of allawance from USPTO on etripamil nasal spray

TIPRANKS
·
19 Feb

Milestone Pharmaceuticals Inc: Receives Notice of Allowance on New U.S. Patent for Etripamil

THOMSON REUTERS
·
19 Feb

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

GlobeNewswire
·
19 Feb

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

GlobeNewswire
·
11 Feb

Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term

Simply Wall St.
·
03 Feb

A Hewlett Packard exec sent a dramatic ‘KILL MIST’ email during its aggressive campaign to crush a rival, court docs revealed. Now HP wants to buy it for $14 billion

Fortune
·
31 Jan

BRIEF-Milestone Pharmaceuticals Provides 2025 Corporate Outlook And To Host Investor Event On Feb 25 In NYC

Reuters
·
28 Jan

Milestone Pharmaceuticals Inc: Pdufa Date of March 27, 2025 for Cardamyst™ (Etripamil) Nasal Spray

THOMSON REUTERS
·
28 Jan

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in Nyc

THOMSON REUTERS
·
28 Jan

Milestone Pharmaceuticals Inc: Plans to Initiate Phase 3 Study in Afib-Rvr in H1 2025

THOMSON REUTERS
·
28 Jan